Protocols
30 protocol(s) meet the specified criteria
Disease Site: Bladder
Protocol No.TitleStatus
16-2171Multi-Institutional Study to Evaluate DNA Methylation Markers For Detection of Primary Bladder Cancers in Urine Samples From a Cohort of Patients with Hematuria.Open
20120139 A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials Open
AMC-095A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin LymphomaOpen
CA209-274A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial CarcinomaOpen
D6410C00001A Phase I, First-Time-in-Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally as a Single Agent in Subjects with Solid Tumors or CTCL and in Combination with Durvalumab and Palliative Radiation in Subjects with Solid TumorsOpen
EA8141-CIRBA Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients with High Grade Upper Tract Urothelial CarcinomaOpen
ETCTN9947-CIRBA Randomized Phase 2 Trial of Cisplatin/Gemcitabine with or without VX-970 in Metastatic Urothelial CarcinomaOpen
GO30140An Open-Label, Multicenter Phase Ib Study of the Safety and Tolerability of Atezolizumab (ANTI-PD L1 Antibody) Administered in combination with Bevacizumab and/or other Treatments in Patients with Solid Tumors.Open
GU14-182A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial CancerOpen
GU15-217UC-GENOME: Urothelial Cancer-GENOnomic analysis to iMprove patient outcomes and rEsearchOpen
INCB-54828-201A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically unresectable Urothelial Carcinoma Harboring FGF/FGFR AlterationsOpen
LCCC1206PORCH: A Registry of Prospective Outcomes of Radical Cystectomy with or without ChemotherapyOpen
LCCC1209Pilot Study of [18F] Fluorodeoxyglucose Positron Emission Tomography-Magnetic Resonance Imaging (FDG-PET-MRI) for Staging of Muscle-Invasive Bladder CancerOpen
LCCC1517Identifying High-Priority Patient-Centered Outcomes in the Postoperative Cystectomy PeriodOpen
LCCC1520Phase 2 study of pembrolizumab in combination with gemcitabine and cisplatin as neoadjuvant therapy prior to radical cystectomy in patients with MIBCOpen
LCCC1527Evaluation of the Chemotherapy Toxicity Risk Score for Treatment Decision in Elderly Patients with Advanced Solid CancerOpen
LCCC1538Geriatric Assessment Reporting in Real Time (GARRT) in non-electively hospitalized older cancer patients: feasibility, impact, and clinician acceptance.Open
LCCC1623Interviewing cancer patients and caregivers about using symptom questionnaires to improve quality of cancer careOpen
LCCC1635Pilot study evaluating the microbiome in bladder and prostate cancer patientsOpen
LCCC1636Using PROMIS as part of routine clinical care for racially diverse prostate and bladder cancer patientsOpen
MCC-16962A Phase I Trial of Dose Escalation of Metformin in Combination with Vincristine, Irinotecan, and Temozolomide in Children with Relapsed or Refractory Solid TumorsOpen
ML28897PRO/02My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients who have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to one of these Agents.Open
NC-6004-004AA Phase 1b/2 Dose Escalation and Expansion Trial of NC-6004 (Nanoparticle Cisplatin) plus Gemcitabine in Patients with Advanced Solid Tumors or Non-Small Cell Lung Cancer, Biliary Tract, and Bladder CancerOpen
PCRC-14-07Caregiver-­‐guided pain management training in palliative careOpen
RAD-IFN-CS-003A Phase III, Open Label Study to Evaluate the Safety and Efficacy of INSTILADRIN® (rAd-IFN/Syn3) Administered Intravesically to Patients with High Grade, BCG Unresponsive, Non-Muscle Invasive Bladder Cancer (NMIBC).Open
S1314-CIRBA Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder CancerOpen
S1602A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal Bcg Before Intravesical Therapy for BCG-Naïve High-Grade Non-Muscle Invasive Bladder CancerOpen
TC-UT-03-PA Phase 3 Multicenter Trial Evaluating the Efficacy and Safety of MitoGel™ on Ablation of Upper Urinary Tract Urothelial CarcinomaOpen
VANDERBILT001A prospective multi-institutional randomized trial evaluating observation versus immediate surgery in the management of low grade noninvasive bladder cancerOpen
WO30070A Phase Iii, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Of Atezolizumab (Anti−Pd-L1 Antibody) In Combination With Gemcitabine/Carboplatin Versus Gemcitabine/Carboplatin Alone In Patients With Untreated Locally Advanced Or Metastatic Urothelial Carcinoma Who Are Ineligible For Cisplatin-Based TherapyOpen